# Bioequivalence Study of Two Inhalation Formulations Containing Budesonide 200 µg

> **NCT02593500** · PHASE1 · COMPLETED · sponsor: **Reig Jofre Group** · enrollment: 57 (actual)

## Conditions studied

- Allergy

## Interventions

- **DRUG:** Budesonida Pulmictan® 200 µg
- **DRUG:** Budesonide 200 µg

## Key facts

- **NCT ID:** NCT02593500
- **Lead sponsor:** Reig Jofre Group
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2015-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02593500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02593500, "Bioequivalence Study of Two Inhalation Formulations Containing Budesonide 200 µg". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02593500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*